Boldenone Undecylenate
Boldenone Undecylenate is an anabolic steroid primarily used in veterinary medicine for horses to promote weight gain, appetite stimulation, and increased red blood cell production. While some bodybuilders and athletes have used it off-label, it is not approved for human use by the FDA and carries significant health risks including cardiovascular complications, hormonal imbalances, and liver toxicity.
Veterinary anabolic steroid used to promote muscle growth and appetite in horses, not approved for human medical use.
Key facts at a glance
- RxNorm
- 2289409
- Generic
- Boldenone Undecylenate
- Class
- pin-variant
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid completely
do not use during pregnancy. Boldenone is an anabolic steroid with known teratogenic potential and can cause fetal harm including masculinization of female fetuses
regular fetal ultrasound and monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid completely
discontinue use immediately if pregnancy occurs
regular prenatal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid completely
do not use; may affect fetal growth and development
fetal growth monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid completely
do not use while breastfeeding. Anabolic steroids can pass into breast milk and may harm the infant
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
adolescentsavoid completely
not for use in patients under 18 years of age. Can cause premature epiphyseal closure leading to short stature
not applicable for pediatric use
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderlyuse with extreme caution or avoid
elderly patients may be more susceptible to cardiovascular, hepatic, and prostate adverse effects. Use only if absolutely necessary with close supervision
regular cardiovascular monitoring, liver function tests, PSA screening, and lipid profile
Use with caution and monitor for adverse effects.
renal_impairment
mild renal impairmentreduce dose and monitor closely
use with caution in patients with renal impairment. Anabolic steroids may affect fluid and electrolyte balance
monitor renal function regularly, fluid balance, and electrolytes
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate hepatic impairmentuse with extreme caution or avoid
use with extreme caution in hepatic impairment due to potential hepatotoxic effects. Monitor liver function closely
regular liver function tests including ALT, AST, bilirubin, and hepatic imaging if long-term use is necessary
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Pharmacological classification
Common uses
Therapeutic and non-therapeutic uses
Legal classification (US)
Regulatory status
First introduced
Historical development
Veterinary medicine: promotes weight gain and appetite in horses, increases lean muscle mass, treats wasting conditions. Sometimes used off-label in humans for bodybuilding despite lack of FDA approval for human use.
Anabolic steroid derived from testosterone with strong anabolic and moderate androgenic properties. Promotes protein synthesis, nitrogen retention, and red blood cell production, leading to increased muscle mass and strength.
Not FDA-approved for human use. Schedule III controlled substance with high abuse potential. Associated risks include hepatotoxicity, cardiovascular strain, endocrine disruption, mood changes, and injection site reactions. Requires medical supervision if used; discontinuation should be gradual to avoid hormonal imbalance.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy